An interventional study of Hope Intervention in Critical Care, sponsored by Oslo University Hospital. Recruiting at 4 sites in Norway. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate an interventional program that aims to strengthen hope in intensive care unit (ICU) patients in the rehabilitation phase. The main questions it aims to answer are:
To develop and implement a follow-up service to strengthen hope in ICU patients, and to evaluate the effect on hope in a stepped wedge randomized trial.
To identify possible predictive factors (facilitators and barriers) associated with hope.
Participants will be asked to take part in an ICU follow-up service, a "Hope Intervention" consisting of digital individual- and group conversations. The program will address topics that are important for hope, such as active involvement, social relationships, believes and thoughts of the future.
The investigators will compare the level of hope between participants who have completed the "Hope Intervention" to those that have not yet completed the program.
The ICU patient's situation is challenging as they are acutely ill over a prolonged period of time and receive life sustaining treatment in the ICU.
Having hope and belief in a positive future, even when the prospects of such future are uncertain, may give strength and motivation and possibly improve the outcome in the rehabilitation phase. Hope is scarcely described in ICU patients.
Health care professionals need to learn how to best support ICU patients and promote hope during the rehabilitation period. Therefore, the main aim of the present study is to develop, implement and evaluate a follow up service to former ICU patients to strengthen their hope using a stepped wedge cluster randomized control intervention trial (SW-CRT). The secondary aim is to identify possible predictive factors associated with hope.
The intervention will start after hospital discharge and will be carried out in group sessions.
1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.
This study's planned enrollment of 190 is above the median of 90 across 930 interventional studies indexed under Critical Illness.
Browse Critical Illness studies →Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cluster A will participate in the Hope Intervention shortly after randomization. Prior the intervention the participants will serve as controls.
Behavioral: Hope Intervention
Cluster B will participate in the Hope Intervention when Cluster A ends, approximately four weeks after randomization. Prior the intervention the participants will serve as controls.
Behavioral: Hope Intervention
Cluster C will participate in the Hope Intervention when Cluster B ends, approximately eight weeks after randomization. Prior the intervention the participants will serve as controls.
Behavioral: Hope Intervention
Group meetings after hospital discharge reflecting on themes that may have an impact on hope. The Hope Intervention consists of four group meetings and two individual conversations during a four week period.
Hope
Level of hope will be measured by Herth Hope Index (HHI). Baseline is measured after the patient has been discharged from the hospital. The HHI consists of 12 items measuring levels of hope related to cognitive and affective factors. Item scores range from 1 (strongly disagree) to 4 (strongly agree) and the total score ranges from 12 to 48. A high score indicates higher level of hope.
Time frame: Before hospital admission, baseline and 1, 2 and 3, months after baseline
Social Provsion Scale
Level of social support will be measured by Social Provision Scale (SPS). Baseline is measured after hospital discharge. The SPS consists of 16 assertions about social support that may apply to the individual. Item scores options are; strongly disagree, disagree, agree, and strongly agree. The total score ranges from 16-64, and a high score indicates a high level of social support.
Time frame: Baseline and 1,2 and 3 months after baseline
Charlson comorbidity Index
Data on comorbidity will be measured with Charlson comorbidity Index (CCI) , collected from the medical record. The CCI categorize the patients' comorbidities and each comorbidity has an associated weight (from 1 to 6). The total scor ranges from 0-37, and the higher the score, the more likely the predicted outcome will result in mortality.
Time frame: Baseline
Memorial Symptom Assessment Scale
Level of symptoms is measured by Memorial Symptom Assessment Scale (MSAS). MSAS consist of 28 predefined symptomes, were 0 indicated not having the symptom and 1 indicates having the symptom. Maximum number of predefined symptoms is 28, and indicates a worse outcome. If the respondent answers "yes" on a symptom, they are asked at what time the symptom occured, and to rate the severity and distress of the symptom using a numeric rating scale from 0 to 10. Zero indicating "not at all" and 10 "very much". A higher score indicates a worse outcome. Baseline is measured after hospital discharge.
Time frame: Baseline and 1,2 and 3 months after baseline
General Perceived Self-Efficacy Scale
Level of a general sense of perceived self-efficacy is measured by General Perceived Self-Efficacy Scale (GSE).The short-form scale consists of items, and each item scores on a 4-point scale from 1 (not at all true) to 4 (exactly true). Total score ranges from 5-20, where high scores reflect courage and perseverance and coping both with daily hassles and stressful life events Baseline is measured after hospital discharge.
Time frame: Baseline and 1,2 and 3 months after baseline
Cognitive Failure Questionnaire
Level of cognitive function is measured by the Cognitive Failure Questionnaire (CFQ). The questionnaire has five responses from "never" (0) to "very often" (4). A lower score indicates better cognition. Baseline is measured after hospital discharge.
Time frame: Baseline and 1,2 and 3 months after baseline
Clinical Frailty Score
Clinical Frailty Score (CFS) evaluates the patients' frailty before admission to the hospital. CFS is a nine-item scale to quantify frailty ranging from one (very fit) to nine (terminally ill) with pictographs and description of the frailty level.
Time frame: Before hospital admission
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
Of 405 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 27 months is above that.
Counting every sponsor, half of 409 studies reached it within 21 months; a quarter within 11 and three quarters within 40.
Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.